Technical Data
A2298-89G
APOBEC3A (Apolipoprotein B mRNA Editing Enzyme Catalytic Polypeptide 3A, APOBEC 3A, APOBEC-3A, ARP3, BEDP, bK150C2.1, Catalytic Polypeptide-like 3A, Phorbolin 1, PHO1, PHRBN)
Description:
Applications:
Suitable for use in ELISA. Other applications not tested.

Recommended Dilution:
Peptide ELISA: antibody detection limit dilution 1:8,000.
Western Blot: Preliminary experiments gave an approx 28kD band in Human Spleen, Tonsil and Peripheral Blood Mononucleocyte lysates after 0.1ug/ml antibody staining.

Storage and Stability:
May be stored at 4°C for short-term only. For long-term storage and to avoid repeated freezing and thawing, aliquot and store at -20°C. Aliquots are stable for at least 12 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Peptide Blocking:
Corresponding peptide is available for Peptide Blocking studies. See A2298-89G-P. Antibody is typically 0.5mg/ml and peptide is supplied as a 100ul pellet. When peptide is reconstituted in 200ul water, the concentration would also be 0.5mg/ml. To start, the best ratio would be 1:1 (molar excess of peptide relative to antibody when identical volumes are mixed). Mix equal volumes of peptide and antibody at the required dilution and leave at ambient temperature. It is best is to have two identical blots to be incubated with equal amount of antibody, but one with the antibody pre-adsorbed to the peptide for 20min. Then incubate and develop the two blots in parallel.
TypeIsotypeCloneGrade
PabAffinity Purified
SizeStorageShippingSourceHost
100ug-20°CBlue IceHumanGoat
Concentration:
~0.5mg/ml
Immunogen:
A synthetic peptide from the C-terminus of aa--TSNFNNGIGRHKTY
Purity:
Purified by affinity chromatography.
Form
Supplied as a liquid in Tris saline, pH 7.2, 0.5% BSA, 0.02% sodium azide.
Specificity:
Recognizes human Phorbolin 1.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
Targeting APOBEC3A to the viral nucleoprotein complex confers antiviral activity., Goila-Gaur R, Khan MA, Miyagi E, Kao S, Strebel K., Retrovirology. 2007 Aug 29;4:61.